A budget impact analysis of Spiromax compared with Turbuhaler for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions

Vista senzilla d'ítem
dc.contributor.authorDarbà, Josep
dc.contributor.authorRamírez, Gabriela
dc.contributor.authorGarcía-Rivero, Juan L.
dc.contributor.authorMayoralas, Sagrario
dc.contributor.authorPascual, José Francisco
dc.contributor.authorRoger, Albert
dc.contributor.authorVargas, Diego
dc.contributor.authorBijedic, Adi
dc.date.accessioned2017-03-02T15:37:24Z
dc.date.available2017-03-02T15:37:24Z
dc.date.issued2016-09
dc.date.updated2017-03-02T15:37:24Z
dc.description.abstractTo assess the economic impact of the introduction of DuoResp(®) Spiromax(®) by focusing on a potential improvement in the inhalation technique to strengthen medication adherence for the treatment of moderate to severe asthmatics in Spain and five Spanish regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ...
dc.format.extent10 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec668397
dc.identifier.issn1178-6981
dc.identifier.pmid27660476
dc.identifier.urihttps://hdl.handle.net/2445/107753
dc.language.isoeng
dc.publisherDove Medical Press
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.2147/CEOR.S111453
dc.relation.ispartofClinicoeconomics and Outcomes Research, 2016, vol. 8 , p. 435-444
dc.relation.urihttps://doi.org/10.2147/CEOR.S111453
dc.rightscc-by-nc (c) Darbà, Josep et al., 2016
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es
dc.sourceArticles publicats en revistes (Economia)
dc.subject.classificationAdministració de medicaments
dc.subject.classificationAsma
dc.subject.classificationMalalties pulmonars obstructives cròniques
dc.subject.classificationTractament tèrmic
dc.subject.classificationEconomia de la salut
dc.subject.otherAdministration of drugs
dc.subject.otherAsthma
dc.subject.otherChronic obstructive pulmonary diseases
dc.subject.otherHeat treatment
dc.subject.otherMedical economics
dc.titleA budget impact analysis of Spiromax compared with Turbuhaler for the treatment of moderate to severe asthma: a potential improvement in the inhalation technique to strengthen medication adherence could represent savings for the Spanish Healthcare System and five Spanish regions
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
668397.pdf
Mida:
270.56 KB
Format:
Adobe Portable Document Format
Descarregar

Col·leccions

Articles publicats en revistes (Economia)